For example, lung and colorectal cancers that harbor mutations in the KRAS oncogene are unresponsive to treatment with anti-EGFR agents[4], and inactivating PTEN mutations (or protein loss) in glioblastomas predict resistance to erlotinib[5]. This evidence concerns the gene KRAS and colorectal cancer.